GridAI Technologies Corp. IPO Filing Research

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1/A in the pre-IPO sequence.

2026-05-28 · 0001104659-26-067071

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows EFFECT and ends the active registration process.

GridAI Technologies Corp. has requested the withdrawal of its S-1 registration statement filed on May 12, 2025, citing no intention to proceed with the contemplated securities offering. The registration was never declared effective, and no securities were sold. The company also seeks credit for fees paid to the SEC under Rule 457(p).

2026-03-17 · 0001104659-26-028766

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

2025-09-17 · 0001104659-25-090498

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The current filing marks the effectiveness of Entero Therapeutics, Inc.'s S-1 registration statement, allowing the sale of 4,945,510 shares of common stock by selling stockholders. The company is not receiving proceeds from the sale of these shares but will benefit from cash proceeds upon exercise of warrants. The shares are listed on Nasdaq under the ticker ENTO, with a recent closing price of $2.32 as of September 9, 2025. The filing includes a risk factor section highlighting the high risks of investing in the company's securities.

2025-09-15 · 9999999995-25-002964

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

4,945,510 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker ENTO · Includes 1,626,282 pre-funded warrants and 3,319,228 common warrants · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

GridAI Technologies Corp. (formerly Entero Therapeutics, Inc.) is a biopharmaceutical company focused on developing targeted therapies for gastrointestinal diseases. The current S-1/A filing reflects updates following a rescission agreement that reversed a prior merger with ImmunogenX, LLC, leading to the disposal of related assets and liabilities. The company is advancing its lead candidate, Adrulipase, for exocrine pancreatic insufficiency, while discontinuing previous programs. The filing also clarifies that the company will not receive proceeds from the sale of shares by selling stockholders but may benefit from cash proceeds from warrant exercises.

2025-09-10 · 0001104659-25-089120

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1/A in the pre-IPO sequence.

4,945,510 shares

Common · Exchange Nasdaq Capital Market · Ticker ENTO · Includes 1,626,282 pre-funded warrants and 3,319,228 common warrants · Selling stockholders only · Use of proceeds No proceeds to the issuer; proceeds from warrant exercises · Flags warrants

GridAI Technologies Corp. is registering 4,945,510 shares of common stock for resale by selling stockholders, with no direct proceeds to the company. The filing includes a rescission agreement to unwind a 2024 merger with ImmunogenX, LLC, leading to the disposal of related assets and liabilities. The company focuses on developing non-systemic therapies for gastrointestinal diseases, with Adrulipase as its primary candidate, while discontinuing prior programs.

2025-08-26 · 0001104659-25-083105

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.50 · 12,000,000 shares · Gross proceeds $6,000,000

Common Stock · Exchange Nasdaq · Ticker ENTO · Pre-funded warrants exercisable for common stock at $0.0001 per share · Use of proceeds Proceeds will be used for general corporate purposes · Flags warrants · Underwriters WESTPARK CAPITAL, INC.

Entero Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company is offering 12 million shares of common stock and pre-funded warrants to purchase 12 million shares, with an estimated public offering price of $0.50 per share. Key developments include the discontinuation of prior programs (Latiglutenase, Capeserod, Niclosamide) and a March 2024 merger with ImmunogenX, Inc., which added assets and liabilities. The company remains a smaller reporting company and highlights risks related to regulatory approval, clinical trials, and reliance on a single product candidate, Adrulipase.

2025-07-02 · 0001104659-25-065403

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.50 · 12,000,000 shares · Gross proceeds $6,000,000

Common Stock · Exchange Nasdaq · Ticker ENTO · Pre-funded warrants exercisable at $0.0001 per share · Underwriters Westpark Capital, Inc.

GridAI Technologies Corp. (formerly Entero Therapeutics, Inc.) is conducting an IPO offering 12,000,000 shares of common stock and pre-funded warrants for 12,000,000 shares. The filing reflects updates including a name change from First Wave Biopharma to Entero Therapeutics in May 2024, a merger with ImmunogenX, Inc. in March 2024, and adjustments to share offerings and pricing. The company focuses on developing non-systemic therapies for gastrointestinal diseases, with Adrulipase as its primary program following the discontinuation of previous initiatives.

2025-06-23 · 0001104659-25-061668

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.39 · 15,228,426 shares

Common · Exchange Nasdaq · Ticker ENTO · Pre-funded warrants to purchase common stock · Use of proceeds General corporate purposes · Flags smaller_reporting_company · Underwriters Westpark Capital, Inc.

GridAI Technologies Corp. (formerly Entero Therapeutics, Inc.) is conducting an IPO to raise capital for its research and development of targeted therapies for gastrointestinal diseases. The company has amended its S-1 filing (S-1/A) to adjust the number of shares offered and pricing, reflecting a revised public offering price of $0.394 per share compared to the previous $0.36. The filing also highlights a March 2024 merger with ImmunogenX, Inc., which added biologic programs like Latiglutenase for celiac disease. The company remains focused on advancing its lead candidate, Adrulipase, while discontinuing prior programs.

2025-06-05 · 0001104659-25-056916

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

Price $0.36 · 16,666,667 shares · Gross proceeds $6,000,000

Common Stock · Exchange Nasdaq · Ticker ENTO · Pre-funded warrants to purchase 16,666,667 shares of common stock at $0.0001 per share · Use of proceeds Proceeds will be used for general corporate purposes · Underwriters Westpark Capital, Inc.

GridAI Technologies Corp. (formerly Entero Therapeutics, Inc.) is conducting an IPO to raise capital through the offering of 16,666,667 shares of common stock and pre-funded warrants. The company, focused on developing non-systemic therapies for gastrointestinal diseases, recently merged with ImmunogenX, Inc., acquiring biologics like Latiglutenase. The offering includes a name change from First Wave Biopharma to Entero Therapeutics and details about the merger's impact on capital structure and operations.

2025-05-12 · 0001104659-25-047285

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after EFFECT.

Entero Therapeutics, Inc. is offering [•] shares of common stock and pre-funded warrants to purchase [●] shares. The company focuses on developing non-systemic therapies for gastrointestinal diseases, including Adrulipase for cystic fibrosis and chronic pancreatitis. Recent changes include the discontinuation of prior programs (Latiglutenase, Capeserod, Niclosamide) and a merger with ImmunogenX, Inc. in March 2024, resulting in new equity issuances and assumed options/warrants.

2025-04-17 · 0001104659-25-035913

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

1,257,625 shares

of the Warrant Share · Exchange Nasdaq Capital Market · Ticker ENTO · Common warrants with exercise prices of $7.48 (March 2024 Warrants) and $2.70 (May 2024 Warrants) · Selling stockholders only · Use of proceeds Proceeds will be used by selling stockholders for general corporate purposes

2024-06-14 · 0001104659-24-071828

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The filing represents a Notice of Effectiveness for an S-3 form, indicating the SEC has accepted the registration statement for securities. The effectiveness date is June 10, 2024, with the filing referencing a previous effectiveness date of January 17, 2024. The company name in the current filing is Entero Therapeutics, Inc., while the prior filing referenced First Wave BioPharma, Inc., suggesting a potential discrepancy or unrelated entities.

2024-06-10 · 9999999995-24-001807

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $2.95 · 275,000 shares · Gross proceeds $1,079,691

Common · Exchange Nasdaq · Ticker FWBI · 91,000 prefunded warrants to purchase common stock at $2.9499, each coupled with a common warrant exercisable at $0.0001 · Use of proceeds General corporate purposes · Flags warrants

2024-05-13 · 0001104659-24-060642

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $7.61 · 173,100 shares · Gross proceeds $4,000,006

Common · Exchange Nasdaq Capital Market · Ticker FWBI · 352,525 Prefunded Warrants to purchase up to 352,525 Shares of Common Stock, each with a $0.0001 exercise price · Use of proceeds Proceeds to us before expenses are used for general corporate purposes · Flags warrants · Underwriters Roth Capital Partners, LLC

2024-03-04 · 0001104659-24-030561

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

1,762,674 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Warrants with an exercise price of $5.00 per share, expiring five years from the initial exercise date · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

2024-01-18 · 0001104659-24-004799

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows RW and marks the registration effective.

First Wave BioPharma, Inc. withdrew its previous S-1 registration statement for a securities offering and now has an S-3 registration statement declared effective. The company elected not to proceed with the earlier public offering, and the new S-3 filing indicates a potential future securities offering under a different registration statement.

2024-01-17 · 9999999995-24-000141

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows S-1/A and ends the active registration process.

First Wave BioPharma, Inc. has withdrawn its previously filed Registration Statement on Form S-1 for its proposed IPO. The company cited its decision not to proceed with the public offering at this time, noting the registration was never declared effective and no securities were issued or sold. The withdrawal request was submitted under Rule 477 of the Securities Act, with the company seeking to credit fees paid to the SEC for future filings.

2023-12-28 · 0001104659-23-129972

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $3.62 · 1,381,215 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Common warrants to purchase shares of common stock at $0.0001 exercise price, exercisable upon issuance, expiring 5 years from issuance. Pre-funded warrants exercisable for one share of common stock at $0.0001 per share. · Use of proceeds Working capital and other general corporate purposes. · Flags warrants · Underwriters Roth Capital Partners, LLC

GridAI Technologies Corp. is conducting an updated IPO offering, adjusting the share and warrant structure compared to its previous filing. The current offering includes up to 1,381,215 shares of common stock, 1,381,215 pre-funded warrants, and 2,762,430 common warrants, with a combined public offering price of $3.62 per share and warrants. This reflects a reduction in share volume and a lower price compared to the prior filing, which had a $6.20 assumed price. The company also notes a reverse stock split effective December 18, 2023, impacting share and price calculations.

2023-12-27 · 0001104659-23-129494

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $6.20 · 2,096,774 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Common warrants to purchase up to 3,145,161 shares and pre-funded warrants to purchase up to 2,096,774 shares · Use of proceeds working capital · Flags warrants · Underwriters Roth Capital Partners, LLC

GridAI Technologies Corp. (First Wave BioPharma, Inc.) filed an S-1/A registration statement for an IPO, detailing an offering of up to 2,096,774 shares of common stock, 2,096,774 pre-funded warrants, and 3,145,161 common warrants. The filing includes a reverse stock split effective December 18, 2023, adjusting share counts and prices. It also outlines the use of proceeds, distribution plan, and risks related to compliance, capital availability, and market liquidity.

2023-12-18 · 0001104659-23-126525

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Common warrants to purchase shares and pre-funded warrants exercisable for shares · Use of proceeds Proceeds to be used for general corporate purposes · Flags warrants · Underwriters Roth Capital Partners, LLC

First Wave BioPharma, Inc. is conducting an IPO offering up to shares of common stock, along with pre-funded warrants and common warrants, with a combined public offering price yet to be determined. The offering is managed by Roth Capital Partners as the exclusive placement agent, with proceeds intended for general corporate purposes. The company's common stock is listed on Nasdaq, and the prospectus highlights risks related to market volatility, lack of established trading markets for warrants, and dependence on capital raising.

2023-11-03 · 0001104659-23-114334

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

11,764,072 shares · Gross proceeds $0.00

Common Stock of First Wave BioPharma, Inc. · Exchange Nasdaq Capital Market · Ticker FWBI · Warrants exercisable at $0.43 per share, expiring 5 years from initial exercise date · Selling stockholders only · Use of proceeds No proceeds to the company; selling stockholders reselling shares

2023-10-02 · 0001104659-23-105674

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

The current filing confirms the effectiveness of GridAI Technologies Corp.'s S-3 registration statement, enabling the company to offer up to 610,000 shares of common stock, 2,675,000 pre-funded warrants, and 6,570,000 common warrants. The offering includes a combined public price of $0.64 per share and warrants, with proceeds intended for general corporate purposes. The filing highlights the lack of an established trading market for warrants and risks related to the company's ability to meet financial obligations and operational challenges.

2023-09-29 · 9999999995-23-002911

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.64 · 610,000 shares · Gross proceeds $1,975,989

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · 6,570,000 common warrants with $0.64 exercise price and 2,675,000 pre-funded warrants with $0.0001 exercise price · Use of proceeds General corporate purposes · Flags warrants · Underwriters Roth Capital Partners, LLC

GridAI Technologies Corp. is conducting an IPO offering 610,000 shares of common stock, 6,570,000 common warrants, and 2,675,000 pre-funded warrants at a combined public price of $0.64 per share and warrants. The offering includes structured terms for pre-funded warrants to address ownership thresholds, with shares and warrants separately issued. The company emphasizes its focus on gastrointestinal therapies and recent clinical trial updates, while noting risks related to market liquidity and regulatory uncertainties.

2023-07-20 · 0001104659-23-082794

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The Notice of Effectiveness confirms the registration of GridAI Technologies Corp.'s securities offering under Form S-1, effective July 17, 2023. The company is offering up to 6,578,947 shares of common stock, pre-funded warrants, and common warrants, with an assumed combined public offering price of $1.52 per share. The offering includes a placement agent, Roth Capital Partners, LLC, and highlights risks related to the lack of a public trading market for warrants and uncertainty in raising sufficient proceeds.

2023-07-17 · 9999999995-23-002106

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

GridAI Technologies Corp. is conducting an IPO offering up to 6,578,947 shares of common stock, along with pre-funded warrants and common warrants, at an assumed combined public offering price of $1.52 per share. The offering includes structured securities with specific terms for warrants and pre-funded warrants, targeting investors while addressing ownership thresholds. The company highlights risks related to liquidity, market uncertainty, and reliance on third-party vendors.

2023-07-13 · 0001104659-23-080564

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

6,578,947 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Common warrants to purchase 13,157,894 shares; pre-funded warrants to purchase 6,578,947 shares · Use of proceeds Proceeds will be used for general corporate purposes · Flags warrants · Underwriters Roth Capital Partners, LLC

GridAI Technologies Corp. is conducting an IPO offering up to 6,578,947 shares of common stock, along with pre-funded warrants and common warrants, with an assumed combined public offering price of $1.52 per share. The offering includes shares and warrants issued in a 1:2 ratio, with warrants exercisable at $0.0001 per share. The company has engaged Roth Capital Partners as the exclusive placement agent, with no minimum offering requirements. The offering is set to end within three trading days of the prospectus date, and shares and warrants are expected to be delivered by July 31, 2023.

2023-07-12 · 0001104659-23-080090

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior EFFECT filing.

GridAI Technologies Corp. (formerly First Wave BioPharma, Inc.) is conducting an amended S-1/A filing for an IPO, offering up to 6,578,947 shares of common stock, pre-funded warrants, and common warrants. The offering is priced at $1.52 per share, with shares and warrants issued in a 1:2 ratio. The company, listed on Nasdaq under FWBI, focuses on biopharmaceutical product development, including adrulipase and niclosamide. The filing highlights risks related to market liquidity, regulatory approvals, and dependence on key product candidates.

2023-07-07 · 0001104659-23-078875

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

The current filing marks the effectiveness of Form S-3 for First Wave BioPharma, Inc., transitioning from its previous S-1 filing. The company is offering up to a specified number of common stock shares, pre-funded warrants, and common warrants, with details on pricing, distribution, and risks. The filing highlights the lack of an established trading market for warrants and the role of the placement agent in facilitating the offering.

2023-06-27 · 9999999995-23-001866

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

3,448,664 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Warrants exercisable at $1.15 per share, expiring 5 years from initial exercise date · Selling stockholders only · Use of proceeds Proceeds go to selling stockholders, no issuer proceeds

2023-06-27 · 0001104659-23-075327

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Pre-funded warrants to purchase common stock and common warrants to purchase common stock · Use of proceeds General corporate purposes

The current S-1 filing represents First Wave BioPharma, Inc.'s registration for an upcoming IPO, offering up to shares of common stock, pre-funded warrants, and common warrants. The filing outlines the proposed offering structure, including pricing, placement agent arrangements, and risk disclosures. This follows a previous Notice of Effectiveness (EFFECT) for an S-3 registration, indicating a transition from a shelf registration to a new offering. The company aims to raise capital with no minimum sales requirement, emphasizing potential liquidity risks and uncertainties in fundraising.

2023-06-05 · 0001104659-23-067826

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

GridAI Technologies Corp. (formerly First Wave BioPharma, Inc.) filed an S-3 registration statement with the SEC, effective March 27, 2023. The filing reflects a rebranding from a biopharmaceutical company to a technology-focused entity, with a new company name and updated registration details. The document confirms the effectiveness of the securities offering, aligning with the company's transition to a tech-oriented business model.

2023-03-27 · 9999999995-23-000684

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

3,069,054 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker FWBI · Pre-Funded Warrants exercisable at $0.0001 per share and Common Warrants exercisable at $3.66 per share with 5-year term · Selling stockholders only · Use of proceeds Proceeds from selling stockholders' sales will not be received by the issuer

2023-03-27 · 0001104659-23-037147

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

The current filing confirms the effectiveness of GridAI Technologies Corp.'s registration statement on Form S-3, enabling the public offering of 255,000 shares of common stock alongside common warrants and pre-funded warrants. The offering includes a combined public price of $1.745 per share and warrant, with proceeds intended for general corporate purposes. The filing notes a reverse stock split effective August 26, 2022, and highlights risks related to limited liquidity and no established trading market for the warrants.

2022-12-08 · 9999999995-22-003495

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

12,500,001 shares

Common Stock · Exchange Nasdaq · Ticker FWBI · Pre-Funded Warrants (exercise price $0.0001 per share) and Common Warrants (exercise price $0.7685 per share) · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds from the sale of shares

2022-12-08 · 0001104659-22-125505

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows S-1/A and confirms the priced prospectus.

Price $1.75 · 255,000 shares · Gross proceeds $5,999,682

Common Stock · Exchange Nasdaq · Ticker FWBI · Pre-Funded Warrants (exercise price $0.0001) and Common Warrants (exercise price $1.62) · Use of proceeds Proceeds will be used for general corporate purposes, including working capital and debt repayment · Flags warrants · Underwriters H.C. Wainwright & Co., LLC

GridAI Technologies Corp. is offering 255,000 shares of common stock, along with common warrants and pre-funded warrants, at a combined public offering price of $1.745 per share and warrant. The offering includes pre-funded warrants exercisable for one share at $0.0001 per share, designed for investors exceeding 4.99% ownership thresholds. The company plans to use proceeds for general corporate purposes, with no established trading market for the warrants. The filing reflects adjustments for a reverse stock split and includes risk disclosures about liquidity, market conditions, and reliance on a single placement agent.

2022-10-11 · 0001104659-22-107444

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The filing marks the effectiveness of First Wave BioPharma, Inc.'s S-1 registration statement for an offering of up to 8,219,178 shares of common stock, along with related warrants and pre-funded warrants. The offering price is tied to the company's recent stock price, with a placement agent facilitating sales. The filing includes details on the structure of the offering, risks related to lack of trading markets for warrants, and the company's financial expectations.

2022-10-06 · 9999999995-22-002970

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior EFFECT filing.

First Wave BioPharma, Inc. filed an S-1/A registration statement to offer up to $12 million in common stock and related warrants, with a combined public offering price of $1.46 per share and warrant. The offering includes pre-funded warrants and common warrants, with a placement agent facilitating sales. The filing reflects a reverse stock split adjustment and details about the use of proceeds, liquidity risks, and market uncertainties.

2022-10-06 · 0001104659-22-106780

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $1.46 · 8,219,178 shares · Gross proceeds $12,000,000

Common · Exchange Nasdaq Capital Market · Ticker FWBI · Pre-funded warrants to purchase common stock at $0.0001 per share and common warrants exercisable at $ per share · Use of proceeds working capital and general corporate purposes · Underwriters H.C. Wainwright & Co., LLC

GridAI Technologies Corp. is offering up to 8,219,178 shares of common stock, along with pre-funded and common warrants, in a $12 million public offering. The offering includes a reverse stock split effective August 26, 2022, and details the role of H.C. Wainwright & Co. as the exclusive placement agent. The S-1/A clarifies pricing, fees, and structure compared to the earlier S-1 filing.

2022-09-22 · 0001104659-22-102184

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Gross proceeds $12,000,000

share for thirty share · Exchange Nasdaq Capital Market · Ticker FWBI · Common Stock and Common Warrants · Pre-funded warrants exercisable for common stock at $0.0001 per share and common warrants exercisable at $[price] per share · Use of proceeds Working capital and general corporate purposes · Flags units, warrants · Underwriters H.C. Wainwright & Co., LLC

First Wave BioPharma, Inc. is conducting an IPO offering up to $12 million in common stock and warrants, with a reverse stock split effective August 26, 2022. The offering includes pre-funded warrants and common warrants, with placement agent fees and limited liquidity risks highlighted. The company is transitioning from an S-3 shelf registration to an S-1 filing, detailing specific terms for securities issuance and distribution.

2022-09-14 · 0001104659-22-100084

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The current filing represents the effectiveness of an S-3 registration statement for First Wave BioPharma, Inc., dated August 4, 2022, following a prior effectiveness date in February 2022. The filing indicates the company is eligible to offer securities under the registered shelf filing, with a new file number compared to the previous submission.

2022-08-04 · 9999999995-22-002262

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2022-08-04 · 0001104659-22-086244

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2022-05-24 · 0001104659-22-064224

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2022-03-02 · 0001140361-22-007531

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2022-03-02 · 0001140361-22-007529

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows RW and confirms the priced prospectus.

2022-03-01 · 0001140361-22-007362

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows FWP and marks the registration effective.

The current filing represents the effectiveness of a Form S-3 registration statement for First Wave BioPharma, Inc., following a previous Free Writing Prospectus (FWP) dated July 22, 2021, which outlined a public offering by AzurRx BioPharma, Inc. The S-3 filing enables the company to offer securities under a shelf registration, with the previous FWP detailing a $5.0 million bought deal for AzurRx. The current filing focuses on the effectiveness of the registration statement, allowing future securities offerings subject to SEC guidelines.

2022-02-02 · 9999999995-22-000307

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2022-02-02 · 0001140361-22-003614

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2021-07-26 · 0001654954-21-008218

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows FWP and supplements the active offering with updated prospectus details.

Price $0.55 · 9,090,910 shares · Gross proceeds $5,000,000

Common Stock · Exchange NASDAQ · Ticker AZRX · Over-allotment 1,363,636 · Use of proceeds Milestone payments under license agreements and general corporate purposes · Underwriters H.C. Wainwright & Co.

AzurRx BioPharma increased its public offering from $3.0 million to $5.0 million by expanding the share purchase to 9,090,910 shares at $0.55 per share. The underwriter, H.C. Wainwright & Co., also expanded the option to purchase additional shares from 818,181 to 1,363,636. Proceeds will fund milestone payments, clinical development, and general corporate purposes.

2021-07-23 · 0001654954-21-008139

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows EFFECT and supplements the active offering with updated prospectus details.

Price $0.55 · 5,454,546 shares · Gross proceeds $3,000,000

Common Stock · Exchange NASDAQ · Ticker AZRX · Over-allotment 818,181 · Use of proceeds milestone payments under license agreements and general corporate purposes · Underwriters H.C. Wainwright & Co., LLC

AzurRx BioPharma, Inc. announced a $3.0 million bought deal offering of 5,454,546 common shares at $0.55 per share, with an underwriter option for additional shares. The offering, part of a shelf registration, aims to fund milestone payments, clinical development, and general corporate purposes. The company focuses on targeted GI therapies, including Phase 2 trials for MS1819 and new programs using niclosamide.

2021-07-22 · 0001654954-21-008131

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2021-07-22 · 0001654954-21-008130

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

2021-06-04 · 0001654954-21-006585

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B4 and confirms the priced prospectus.

2021-06-04 · 0001654954-21-006583

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2021-06-04 · 0001654954-21-006581

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The current filing represents an S-3 registration statement effective June 2, 2021, for AzurRx BioPharma, Inc., replacing a previous POS AM submission from April 2021. The change in filing type suggests a shift in the offering strategy, though no substantive details about the company's operations or financials are included in the provided text.

2021-06-02 · 9999999995-21-002190

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The filing confirms the effectiveness of AzurRx BioPharma, Inc.'s securities offering, dated April 8, 2021, under the submission type 'POS AM.' This follows a previous effectiveness notice from February 16, 2021, for an S-3 form, indicating potential updates or amendments to the offering structure.

2021-04-08 · 9999999995-21-001354

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows FWP and confirms the priced prospectus.

2021-03-09 · 0001654954-21-002520

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2021-02-17 · 0001654954-21-001769

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

AzurRx BioPharma, Inc. filed an S-3 registration statement on February 16, 2021, effective at 4:30 PM, replacing a previous S-1 filing from January 21, 2021. The change in filing form suggests a shift in the securities being registered, though no specific details about the offering are provided in the text.

2021-02-16 · 9999999995-21-000665

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2021-01-22 · 0001654954-21-000713

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

The current filing marks the effectiveness of AzurRx BioPharma, Inc.'s S-1 registration statement, enabling the resale of up to 16,000,002 shares of common stock issuable upon conversion of Series C Preferred Stock and exercise of warrants. The filing highlights limitations on beneficial ownership, requiring stockholder approval to increase authorized shares and comply with Nasdaq rules. The company remains an emerging growth company, with restrictions on warrant exercises until approval is obtained.

2021-01-21 · 9999999995-21-000229

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $0.82 · 16,000,002 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker AZRX · Warrants and pre-funded warrants exercisable into common stock · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for working capital

GridAI Technologies Corp. is registering 16,000,002 shares of common stock issuable upon conversion of Series C Preferred Stock and exercise of warrants. The filing outlines limitations on conversions due to beneficial ownership caps, the need for stockholder approval to increase authorized shares, and the resale of shares by a selling stockholder without direct proceeds to the company. The company remains an emerging growth company with limited operating history.

2021-01-13 · 0001654954-21-000392

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows FWP and confirms the priced prospectus.

2021-01-05 · 0001654954-21-000092

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows RW and marks the registration effective.

The filing represents the effectiveness of a new Form S-3 registration statement for AzurRx BioPharma, Inc., replacing a previously withdrawn registration. The company withdrew its initial S-3 filing (File No. 333-236333) to restructure the offering under a separate registration (File No. 333-240129), which became effective on September 21, 2020. No securities were sold under the withdrawn registration.

2020-09-21 · 9999999995-20-002515

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2020-09-21 · 0001654954-20-010271

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows EFFECT and ends the active registration process.

AzurRx BioPharma, Inc. requested the withdrawal of its Registration Statement on Form S-3 (File No. 333-236333) effective immediately. The company opted to include the offered shares in a separate Form S-3 (File No. 333-240129) filed on July 27, 2020. The original registration was never declared effective, and no securities were sold under it.

2020-09-17 · 0001654954-20-010208

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2020-01-17 · 0001654954-20-000575

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

AzurRx BioPharma, Inc. filed a Notice of Effectiveness for its S-1 registration statement, confirming the effectiveness of its securities offering. The filing relates to the sale of up to 8,880,760 shares of common stock by Lincoln Park Capital Fund, LLC, a selling stockholder. The company is a biopharmaceutical firm focused on developing non-systemic biologics for gastrointestinal disorders, with a lead candidate MS1819-SD targeting exocrine pancreatic insufficiency. The offering is part of the company's efforts to raise capital, with the selling stockholder acting as an underwriter. The company is an emerging growth company and has elected reduced reporting requirements.

2020-01-14 · 9999999995-20-000092

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $1.30 · 8,880,760 shares · Gross proceeds $11,544,988

Common stock, par value $0.0001 per share · Exchange Nasdaq Capital Market · Ticker AZRX · Selling stockholders only · Use of proceeds Proceeds go to the selling stockholder, not the company · Underwriters Lincoln Park Capital Fund, LLC

AzurRx BioPharma, Inc. is offering up to 8,880,760 shares of common stock through a revised registration statement (S-1/A). The filing highlights progress in clinical trials for MS1819-SD, a yeast-derived lipase for exocrine pancreatic insufficiency, including positive Phase 2 results and initiation of a Combination Trial with PERT. The company also details a 2019 Asset Purchase Agreement with Mayoly for MS1819-SD rights and updates on its b-lactamase program for antibiotic-associated diarrhea. The filing emphasizes risks related to clinical trial outcomes, regulatory approval, and dependence on a single drug candidate.

2020-01-13 · 0001654954-20-000383

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $1.07 · 8,880,760 shares · Gross proceeds $9,502,414

Common · Exchange Nasdaq Capital Market · Ticker AZRX · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters Lincoln Park Capital Fund, LLC

GridAI Technologies Corp. (AzurRx BioPharma) is a biopharmaceutical company focused on developing non-systemic biologics for gastrointestinal disorders. The current S-1 filing outlines its pipeline, including MS1819-SD for exocrine pancreatic insufficiency (EPI) and a beta-lactamase program to address antibiotic-resistant infections. Recent updates include positive Phase 2 trial results for MS1819-SD, a completed asset purchase agreement with Mayoly, and plans for Phase 2b/3 trials. The company has not yet commercialized products and remains an emerging growth company.

2019-12-31 · 0001654954-19-014339

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 8-A12B and confirms the priced prospectus.

2019-07-19 · 0001654954-19-008366

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2019-07-17 · 0001654954-19-008322

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The filing confirms the effectiveness of AzurRx BioPharma, Inc.'s S-3 registration statement on June 25, 2019, 18 days after the previous effectiveness date of June 7, 2019. The filing relates to a shelf registration statement (File Number 333-231954) with no apparent changes to the company's structure or offering details compared to the prior submission.

2019-06-25 · 9999999995-19-001439

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows FWP and confirms the priced prospectus.

2019-06-21 · 0001654954-19-007552

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The current filing for AzurRx BioPharma, Inc. became effective on June 7, 2019, under Form S-3, following a previous effectiveness date of July 12, 2018. Both filings relate to shelf registration statements, allowing the company to offer securities without immediate prospectus disclosure.

2019-06-07 · 9999999995-19-001307

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2019-05-09 · 0001654954-19-005503

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

2019-04-02 · 0001654954-19-003927

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

AzurRx BioPharma, Inc. filed an S-3 registration statement that became effective on July 12, 2018, following a prior S-3 filing effective November 17, 2017. The filings indicate the company's ongoing regulatory compliance and shelf registration activity, though no substantive updates or changes to business operations are explicitly detailed.

2018-07-12 · 9999999995-18-001784

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows DRS/A and confirms the priced prospectus.

2018-05-02 · 0001654954-18-004623

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows DRS/A and confirms the priced prospectus.

2018-04-30 · 0001654954-18-004528

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows DRS and confirms the priced prospectus.

2018-01-19 · 0001654954-18-000589

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows RW and marks the registration effective.

AzurRx BioPharma, Inc. withdrew its previously filed S-3 registration statement due to not meeting eligibility requirements for Form S-3 at the time of filing. The registration statement, submitted on October 11, 2017, was never declared effective, and no securities were sold. The company requested the Commission to consent to the withdrawal and credit fees paid for future use.

2017-11-17 · 9999999995-17-003015

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows EFFECT and ends the active registration process.

AzurRx BioPharma, Inc. submitted a request to withdraw its Form S-3 registration statement filed on October 11, 2017, due to not meeting eligibility requirements for Form S-3 at the time of filing. The registration statement was never declared effective, and no securities were sold under it.

2017-10-31 · 0001654954-17-009854

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

First tracked pre-IPO filing for this issuer.

2017-08-15 · 0001654954-17-007594

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The filing confirms the effectiveness of AzurRx BioPharma, Inc.'s Form S-1 registration statement for 5,905,535 shares of common stock, including shares from warrants, convertible debentures, and escrowed warrants. The registration allows selling stockholders to resell shares, with no proceeds to the company from the sales but potential future proceeds from warrant exercises. The company's stock is listed on NASDAQ under AZRX.

2017-08-11 · 9999999995-17-002100

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

5,905,535 shares

Common Stock, par value $0.0001 per share · Exchange NASDAQ Capital Market · Ticker AZRX · Common stock purchase warrants exercisable for 4,063,420 shares, plus 164,256 in escrow · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, up to $21.75 million

The current S-1/A filing by AzurRx BioPharma, Inc. relates to the registration of up to 5,905,535 shares of common stock for sale by selling stockholders, including shares from convertible debentures, warrants, and escrowed warrants. The filing emphasizes the company's focus on developing non-systemic biologics for gastrointestinal disorders, with two lead candidates in clinical development. The prospectus highlights risks related to clinical trials, regulatory approval, and market competition.

2017-08-09 · 0001654954-17-007098

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

5,895,535 shares · Gross proceeds $0.00

Common Stock · Exchange NASDAQ CAPITAL MARKET · Ticker AZRX · 4,063,420 shares issuable upon exercise of common stock purchase warrants held by selling stockholders and 164,256 shares issuable upon exercise of escrowed warrant held by Lincoln Park Capital Fund, LLC · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, will be used for general corporate purposes · Flags warrants

The current S-1 filing by AzurRx BioPharma, Inc. relates to the sale of up to 5,895,535 shares of common stock by selling stockholders, including shares from convertible debentures, warrants, and escrowed warrants. This follows an earlier 2016 initial public offering (IPO) of 960,000 shares at $5.50 per share. The S-1 emphasizes the company's focus on non-systemic biologics for gastrointestinal disorders, with two lead candidates in development: MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing antibiotic-associated infections. The filing also outlines the use of proceeds and risks associated with clinical trials, regulatory approval, and financial obligations.

2017-07-21 · 0001654954-17-006580

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $5.50 · 960,000 shares · Gross proceeds $4,804,800

Common Stock · Exchange NASDAQ · Ticker AZRX · Over-allotment 144,000 · Flags emerging_growth_company · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc., ViewTrade Securities Inc.

AzurRx BioPharma, Inc. is conducting its initial public offering (IPO) of 960,000 shares of common stock at $5.50 per share, with proceeds totaling $5.28 million. The company focuses on developing non-systemic biologics for gastrointestinal disorders, including MS1819 for exocrine pancreatic insufficiency and AZX1101 to protect gut microbiota from antibiotic damage. The filing highlights emerging growth company status under the JOBS Act, allowing reduced reporting requirements, and outlines risks related to clinical trial outcomes, regulatory approvals, and financial constraints.

2016-10-13 · 0001654954-16-002783

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The filing represents the effectiveness of AzurRx BioPharma, Inc.'s initial public offering (IPO) for 1,200,000 shares of common stock at $5.50 per share, with an additional 180,000 shares reserved for underwriter over-allotments. The company focuses on developing non-systemic biologics for gastrointestinal disorders, including MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing infections and antibiotic-associated diarrhea. The offering is registered under Form S-1, with proceeds intended for clinical trials, manufacturing, and general operations.

2016-10-11 · 9999999995-16-005935

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $5.50 · 1,380,000 shares · Gross proceeds $7,590,000

Common · Exchange NASDAQ · Ticker AZRX · Over-allotment 180,000 · Use of proceeds Working capital, research and development, and clinical trials · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc., ViewTrade Securities Inc.

AzurRx BioPharma, Inc. is conducting an initial public offering (IPO) of 1.2 million shares of common stock at $5.50 per share. The company develops non-systemic biologics for gastrointestinal disorders, with two lead candidates: MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing antibiotic-related infections. The offering aims to fund clinical trials, manufacturing scale-up, and regulatory submissions. The company qualifies as an emerging growth company under the JOBS Act, allowing reduced disclosure requirements.

2016-10-05 · 0001654954-16-002634

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

The filing represents a free writing prospectus (FWP) for AzurRx BioPharma, Inc.'s initial public offering (IPO), updating and superseding the preliminary prospectus included in Amendment No. 6 to the S-1 registration statement. The document outlines the company's focus on developing non-systemic biologics for gastrointestinal disorders, with two therapeutic proteins in its pipeline (MS1819 and AZX1101). The offering involves 1.7 million shares of common stock, with underwriters having an option to purchase additional shares. The prospectus emphasizes the risks associated with the company's early-stage development and regulatory uncertainties.

2016-10-05 · 0001415889-16-007244

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $7.00 · Range $6.00 to $8.00 · 1,700,000 shares · Gross proceeds $11,900,000

Common Stock · Exchange NASDAQ · Ticker AZRX · Over-allotment 255,000 · Use of proceeds for working capital · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc.

AzurRx BioPharma, Inc. is conducting an initial public offering (IPO) of 1,700,000 shares of common stock at an estimated price range of $6.00 to $8.00 per share. The company is developing two non-systemic biologic therapies for gastrointestinal disorders: MS1819 for exocrine pancreatic insufficiency (EPI) and AZX1101 for preventing hospital-acquired infections and antibiotic-associated diarrhea. The offering includes an over-allotment option of 255,000 additional shares. AzurRx is an emerging growth company under the JOBS Act, which allows reduced disclosure requirements. The proceeds will fund clinical trials, formulation work, and operational expenses.

2016-09-19 · 0001654954-16-002254

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

The Free Writing Prospectus (FWP) relates to AzurRx BioPharma, Inc.'s initial public offering (IPO) of common stock, referencing the preliminary prospectus dated September 2, 2016. It serves as a summary of the offering, updates prior disclosures, and emphasizes preliminary information subject to change. The filing highlights the company's focus on non-systemic biologics for gastrointestinal disorders, with two lead candidates in development. The IPO aims to raise capital for clinical trials and product development, with underwriters granted an option for over-allotments.

2016-09-06 · 0001415889-16-007044

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $7.00 · Range $6.00 to $8.00 · 1,700,000 shares · Gross proceeds $13,685,000

Common Stock · Exchange NASDAQ · Ticker AZRX · Over-allotment 255,000 · Use of proceeds working capital, clinical trials, and other general corporate purposes · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc.

GridAI Technologies Corp. (AzurRx BioPharma, Inc.) is conducting an initial public offering (IPO) of 1,700,000 shares of common stock at an estimated price range of $6.00 to $8.00 per share. The company focuses on developing non-systemic biologics for gastrointestinal disorders, with two lead candidates: MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing antibiotic-associated infections. The offering aims to fund clinical trials, formulation work, and regulatory submissions, with proceeds expected to support growth and commercialization efforts.

2016-09-06 · 0001415889-16-007040

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Price $7.00 · Range $6.00 to $8.00 · 2,142,857 shares · Gross proceeds $15,000,000

Common Stock · Exchange NASDAQ · Ticker AZRX · Over-allotment 321,429 · Use of proceeds For formulation work, validation and stabilization testing of MS1819 capsules and conducting the phase IIb clinical trial · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc.

AzurRx BioPharma, Inc. is conducting an initial public offering (IPO) of 2,142,857 shares of common stock at an estimated price range of $6.00 to $8.00 per share. The company focuses on developing non-systemic biologics for gastrointestinal disorders, with two lead candidates in clinical and preclinical stages: MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing antibiotic-related infections. Proceeds will fund clinical trials, formulation work, and regulatory submissions. The company qualifies as an emerging growth company, allowing reduced disclosure requirements under the JOBS Act.

2016-08-09 · 0001415889-16-006739

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows S-1/A and registers the class of securities for exchange listing.

The current 8-A12B filing registers common stock under Section 12(b) of the Securities Exchange Act for listing on NASDAQ, referencing the prior S-1/A registration statement. It incorporates by reference the earlier S-1/A's description of securities and excludes exhibits as no other securities are registered. The filing focuses on registration requirements without additional disclosures beyond what was previously submitted.

2016-08-08 · 0001415889-16-006709

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $7.00 · Range $6.00 to $8.00 · 2,142,857 shares · Gross proceeds $15,000,000

Common Stock · Exchange NASDAQ · Ticker AZRX · Over-allotment 321,429 · Use of proceeds To fund formulation work, validation, stabilization testing, and clinical trials for MS1819 · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc.

GridAI Technologies Corp. is conducting its initial public offering (IPO) of 2,142,857 shares of common stock at an anticipated price range of $6.00 to $8.00 per share. The company, which focuses on developing non-systemic biologics for gastrointestinal disorders, plans to use proceeds from the offering to advance clinical trials for its lead candidates, MS1819 and AZX1101. The IPO follows amendments to its registration statement, with the current filing dated August 5, 2016, and includes an over-allotment option for additional shares.

2016-08-05 · 0001415889-16-006694

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1 and supplements the active offering with updated prospectus details.

Class A · Ticker AZUR · Use of proceeds general corporate purposes · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc.

The current filing is a free writing prospectus for AzurRx BioPharma, Inc.'s initial public offering (IPO) of common stock, updating and superseding the preliminary prospectus included in the prior S-1 registration statement. The document highlights the company's focus on developing non-systemic biologics for gastrointestinal disorders, including two therapeutic proteins in clinical trials (MS1819 and AZX1101). The filing emphasizes preliminary information subject to change, with details on the offering structure, risks, and regulatory considerations.

2016-07-29 · 0001415889-16-006627

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $7.00 · Range $6.00 to $8.00 · 2,142,857 shares · Gross proceeds $15,000,000

Common Stock, $0.0001 par value · Exchange NASDAQ · Ticker AZRX · Over-allotment 321,429 · Use of proceeds general corporate purposes · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc.

AzurRx BioPharma, Inc. is conducting an initial public offering (IPO) for 2,142,857 shares of common stock at an estimated price range of $6.00 to $8.00 per share. The company develops non-systemic biologics for gastrointestinal disorders, with two lead candidates: MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing antibiotic-associated infections. The IPO proceeds will fund clinical trials, formulation work, and preclinical studies. AzurRx is an emerging growth company under the JOBS Act, allowing reduced disclosure requirements.

2016-07-29 · 0001415889-16-006616

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange NASDAQ · Ticker AZRX · Use of proceeds To fund formulation work, validation and stabilization testing for MS1819 capsules and clinical trials · Underwriters WallachBeth Capital, LLC, Network 1 Financial Securities, Inc.

GridAI Technologies Corp. (AzurRx BioPharma, Inc.) is conducting an initial public offering (IPO) of common stock to fund the development of its non-systemic biologics for gastrointestinal disorders. The company is focused on two therapeutic proteins: MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing antibiotic-associated infections. The IPO aims to raise capital for clinical trials, preclinical studies, and general corporate purposes. AzurRx is an emerging growth company under the JOBS Act, allowing it to use simplified reporting requirements.

2016-07-13 · 0001415889-16-006483

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

GridAI Technologies Corp. (formerly AzurRx BioPharma, Inc.) is conducting an initial public offering (IPO) of common stock, aiming to list on NASDAQ under the symbol 'AZRX.' The company focuses on developing non-systemic biologics for gastrointestinal disorders, with two lead candidates: MS1819 for exocrine pancreatic insufficiency and AZX1101 for preventing antibiotic-associated infections. The IPO proceeds will fund clinical trials, preclinical development, and general corporate purposes. The company qualifies as an 'emerging growth company' under the JOBS Act, allowing reduced disclosure requirements.

2016-06-16 · 0001415889-16-006238

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

GridAI Technologies Corp. is a clinical development-stage biopharmaceutical company focused on advancing two product candidates, MS1819 and AZX1101, through pre-clinical and clinical trials. The company has not generated revenue, incurred significant losses, and relies on external financing for operations. The current filing includes pro forma financial adjustments related to an upcoming IPO, reflecting the conversion of preferred stock and notes into common stock, as well as estimated net proceeds from the offering.

2015-10-16 · 0001415889-15-003435

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

GridAI Technologies Corp. is a clinical development-stage biopharmaceutical company with no revenue, significant accumulated losses, and two product candidates (MS1819 and AZX1101) in early development. The filing outlines pro forma financial data reflecting potential stock conversions and common stock issuances prior to the IPO, aiming to fund phase IIb trials for MS1819 and preclinical work for AZX1101. The company faces risks related to regulatory approval, clinical trial delays, and dependence on future financing.

2015-09-08 · 0001415889-15-003007

GridAI Technologies Corp.

Filing Timeline

14 comparable deals

Recent News